GENVEC RECEIVES NIAID BIODEFENSE PROGRAM GRANT FOR DEVELOPMENT OF BROADLY APPLICABLE VACCINE TECHNOLOGY

GenVec, Inc. announced that it has received a $430,000 Phase I Small Business Innovation Research award from the National Institute of Allergy and Infectious Diseases Biodefense Program to support the company's efforts to develop novel adenovector-based vaccine technology. The funding will support research to advance GenVec's adenovector technology to develop a range of vaccines based on novel serotypes of adenovirus. The new vectors produced under this grant will incorporate influenza genes to assess their improved immunogenicity. BioSpace (http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20060829005381&ndmHsc=v2*A1156244400000*B1156885151000*DgroupByDate*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view)